Menu
Back to Journals » Biologics: Targets and Therapy » Volume 7
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Authors Walsh G
Received 23 November 2012
Accepted for publication 14 December 2012
Published 9 January 2013 Volume 2013:7 Pages 7—11
DOI https://doi.org/10.2147/BTT.S30133
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Garry M Walsh
Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
Abstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
Keywords: IL-5, asthma, eosinophil
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.